このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Austar Lifesciences 将来の成長

Future 基準チェック /06

現在、 Austar Lifesciencesの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Life Sciences 収益成長	53.3%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

Aug 28

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Austar Lifesciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:6118 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2024	1,545	-19	-20	22	N/A
3/31/2024	1,654	-26	-77	-20	N/A
12/31/2023	1,764	-33	-134	-63	N/A
6/30/2023	1,972	51	-136	-60	N/A
3/31/2023	2,065	78	-155	-49	N/A
12/31/2022	2,157	104	-174	-38	N/A
9/30/2022	2,246	96	-233	-81	N/A
6/30/2022	2,264	105	-291	-125	N/A
3/31/2022	2,139	191	-255	-114	N/A
12/31/2021	2,015	277	-219	-103	N/A
9/30/2021	1,824	258	-128	-32	N/A
6/30/2021	1,633	238	-36	40	N/A
3/31/2021	1,465	136	-26	46	N/A
12/31/2020	1,296	33	-15	52	N/A
9/30/2020	1,193	25	-11	48	N/A
6/30/2020	1,089	17	-7	43	N/A
3/31/2020	1,069	12	8	41	N/A
12/31/2019	1,049	8	23	38	N/A
9/30/2019	1,007	8	-33	-4	N/A
6/30/2019	966	8	-89	-46	N/A
3/31/2019	891	4	-104	-62	N/A
12/31/2018	817	0	-119	-78	N/A
9/30/2018	724	-16	-63	-37	N/A
6/30/2018	631	-33	-7	4	N/A
3/31/2018	589	-43	N/A	-1	N/A
12/31/2017	547	-54	N/A	-6	N/A
9/30/2017	587	-43	N/A	-20	N/A
6/30/2017	628	-32	N/A	-33	N/A
3/31/2017	650	-25	N/A	-32	N/A
12/31/2016	673	-19	N/A	-30	N/A
9/30/2016	648	-17	N/A	3	N/A
6/30/2016	624	-16	N/A	37	N/A
3/31/2016	626	-5	N/A	49	N/A
12/31/2015	628	6	N/A	62	N/A
9/30/2015	640	24	N/A	26	N/A
6/30/2015	652	43	N/A	-9	N/A
3/31/2015	666	54	N/A	-37	N/A
12/31/2014	680	65	N/A	-64	N/A
9/30/2014	676	58	N/A	-51	N/A
6/30/2014	672	51	N/A	-37	N/A
3/31/2014	689	52	N/A	17	N/A
12/31/2013	705	54	N/A	71	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6118の予測収益成長が貯蓄率 ( 2.3% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 6118の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 6118の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 6118の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 6118の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6118の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Austar Lifesciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Austar Lifesciences Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021

Recent updates

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

First half 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.078 loss in 1H 2023)

Austar Lifesciences Limited to Report First Half, 2024 Results on Aug 27, 2024

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Austar Lifesciences Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: CN¥0.063 loss per share (vs CN¥0.17 profit in FY 2022)

Austar Lifesciences Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

New major risk - Share price stability

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

First half 2023 earnings released: CN¥0.078 loss per share (vs CN¥0.089 profit in 1H 2022)

Investor sentiment deteriorates as stock falls 30%

Austar Lifesciences Limited to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 25%

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.54 in FY 2021)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 25%

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Austar Lifesciences Limited Announces Executive Changes

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

First half 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.42 in 1H 2021)

Investor sentiment deteriorated over the past week

Austar Lifesciences Limited to Report First Half, 2022 Results on Aug 29, 2022

Austar Lifesciences Limited (SEHK:6118) acquired an unknown minority interest in Noozle Fluid Technology (Shanghai) Co., Ltd..

Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Less than half of directors are independent

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Investor sentiment improved over the past week

Austar Lifesciences Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorated over the past week

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

First half 2021 earnings released: EPS CN¥0.42 (vs CN¥0.025 in 1H 2020)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Full year 2020 earnings released: EPS CN¥0.065 (vs CN¥0.016 in FY 2019)

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.016 in FY 2019)

Austar Lifesciences Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

An affiliate of Pall Corporation entered into an agreement to acquire 60% in PALL-AUSTAR Lifesciences Limited from Austar Lifesciences Limited (SEHK:6118) for approximately CNY 220 million.

New 90-day high: HK$6.15

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

New 90-day high: HK$4.02

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

First half earnings released

New 90-day low - HK$3.18

First half earnings released

Austar Lifesciences Limited to Report First Half, 2020 Results on Aug 27, 2020

New 90-day low - HK$3.23

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率